Oxford Population Health and SomaLogic deliver 28 million proteomic data points on China Kadoorie Biobank samples

BOULDER, Colo., March 13, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, recently completed the 7,000-plex assay on and delivered data for 4,000 plasma samples from the China Kadoorie Biobank (CKB), one of the world’s largest prospective studies. The SomaLogic team provided more than 28 million data points from the assay which will be combined with other available genetic, lifestyle, anthropometric and health outcome data to address a range of research questions. This work builds on a successful history of SomaScan® Platform utilization in some of the world’s largest population proteomics biobank projects, including the EPIC, MESA, Fenland, Whitehall II, HUNT3, CRIC, COPD Gene, Spiromics, deCODE and ARIC datasets.

Professor Zhengming Chen, Richard Peto Professor of Epidemiology at Oxford Population Health and UK-Principal Investigator of the China Kadoorie Biobank, said “The large-scale application of proteomics assays in big population biobanks such as CKB will be a game changer. Building on the experience gained in these initial 4,000 samples, we will seek to extend the use of the proteomic assay to a much larger number of samples in the near future.”

The China Kadoorie Biobank (www.ckbiobank.org) was established to investigate the main genetic and environmental causes of common chronic diseases in the Chinese population. Between 2004 and 2008, over 510,000 adults were recruited from ten geographically defined regions of China, with extensive data collection by questionnaire and physical measurements, and with long-term storage of blood samples for future study. All participants are now being monitored for fatal and non-fatal health outcomes through linkage with established registries and health insurance databases in the study areas.

This large, well-established study will be a uniquely powerful and rich resource for investigating the main causes of many common chronic diseases over the next few decades, and the information generated has the potential to improve understanding of disease etiology, risk prediction and development of new treatments. The project is a long-term collaboration between Oxford Population Health, Peking University and the Chinese Academy of Medical Sciences.

SomaLogic’s proprietary SomaScan Platform is designed to be a universal platform that can be applied across research and discovery, translational research and biopharmaceutical development, and clinical applications. SomaLogic can run approximately 7,000 protein measurements on a single 55 microliter plasma or serum sample. The company has run more than 550,000 samples to date.

About SomaLogic 
SomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com .  

About Oxford Population Health
Oxford Population Health (the Nuffield Department of Population Health) is a world-leading research institute, based at the University of Oxford, that investigates the causes and prevention of disease.

We have over 750 staff, students and academic visitors working in a number of world-renowned population health research groups, including the Cancer Epidemiology Unit (CEU), Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), and the National Perinatal Epidemiology Unit (NPEU), and other groups working on public health, health economics, ethics and health record linkage. Oxford Population Health is also a key partner in the Oxford University Big Data Institute.

https://www.ndph.ox.ac.uk/

Forward Looking Statements Disclaimer
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements, other than statements of historical fact included in this press release, regarding our strategy, future operations, financial position, estimated revenues, projections, prospects, plans and objectives of management are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “forecast,” “guidance,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “continue,” “will likely result,” “possible,” “potential,” “predict,” “pursue,” “target” and similar expressions, although not all forward-looking statements contain such identifying words. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors.   Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including factors which are beyond SomaLogic’s control. You should carefully consider these risks and uncertainties, including, but not limited to, those factors described under Part I, Item 1A – “Risk Factors” in our Annual Report on Form 10-K and other filings we make with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SomaLogic assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company will not and does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Media Contact  
Emilia Costales  
720-798-5054  
ecostales@somalogic.com   

Investor Contacts 
Lauren Glaser
Lglaser@somalogic.com

Marissa Bych 
Gilmartin Group LLC 
Marissa@gilmartinir.com


Oxford Population Health and SomaLogic deliver 28 million proteomic data points on China Kadoorie Biobank samples

TIN LIÊN QUAN

Neuronetics Sponsors the 5th International Brain

Poster Session Highlights the Strong Dose-Response Relationship and the Importance of Treating Beyond 30 Treatments With NeuroStar Advanced Therapy...

New Clinical Studies Demonstrate that Sword Health Improves

The studies are the first to evaluate how underserved patient populations progress when given access to a digital care program- In Study #1 Black and...

GDS to Report Fourth Quarter and Full Year 2022 Financial

SHANGHAI, China, March 05, 2023 (GLOBE NEWSWIRE) -- GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading...

Wish to Participate in Loop Capital Markets 2023 Virtual

SAN FRANCISCO, March 06, 2023 (GLOBE NEWSWIRE) -- ContextLogic Inc. (d/b/a Wish) (NASDAQ: WISH), one of the world’s largest mobile ecommerce platforms,...

DentaQuest Opens Nominations for 2023 Health Equity Heroes

The awards recognize individuals and organizations working toward equitable access to oral care and optimal health outcomes...

Amid Global Health Worker Shortage, CGFNS Assembles Board

PHILADELPHIA, Feb. 22, 2023 (GLOBE NEWSWIRE) -- With a global health worker shortage accelerating the demand for internationally educated nurses in...

Esten & Richard Agency Joins World Insurance Associates

Iselin, NJ, Feb. 27, 2023 (GLOBE NEWSWIRE) -- World Insurance Associates LLC (World), a Top 50 Insurance Brokerage, announced today that it acquired the...

Genetic Testing Market Size to Hit USD 17.48 Billion by

Genetic Testing Market Size and Trends Analysis By Type (Prescribed Genetic Testing and Direct-to-Consumer Genetic Testing), Method (Molecular Genetic...

THỦ THUẬT HAY

So sánh OPPO A39 và Samsung J5 2016: Hiệu năng và pin

Nên chọn OPPO A39 (Neo 9s) hay Samsung J5 2016? Đánh giá sức mạnh hiệu năng và thời lượng pin trên 2 thiết bị nổi bật nhất trong tầm giá 5 triệu

Quay video lặp đi lặp lại một cách thú vị hơn với Loop Camera trên Zalo

Tính năng khoảng khắc trên Zalo đã cho phép người dùng quay video lặp đi lặp lại một cách thú vị hơn với Loop Camera. Người dùng iOS và Android đã từng say mê những video lặp đi lặp lại cực vui trên Snapchat, thì không

Hỏi đáp: Tại sao người dùng smartphone Android lại thích cài theme iPhone?

Nếu thích iOS sao các bạn ấy lại không dùng iphone luôn cho tiện? Có 'thánh' nào cũng thích dùng theme giống iOS trên Android không?

Cách tìm ghi chú trên iPhone trong một nốt nhạc với thẻ Tags iOS 15

Với iOS 15, Apple đã bổ sung thẻ Tags trong ứng dụng Ghi chú trên iPhone để bạn tìm nhanh hơn nhiều. Sau đây là cách tìm ghi chú trên iPhone bằng thẻ Tags nhé...

Chia sẻ cách xem lịch học trực tuyến trên truyền hình nhanh chóng, tiện lợi cho học sinh

Đài truyền hình đã phát sóng những buổi học trên sóng truyền hình trong mùa dịch bệnh để giúp học sinh có kiến thức trong điều kiện không thể đến trường. Bài viết dưới đây cũng sẽ giúp bạn cách xem lịch học trực tuyến

ĐÁNH GIÁ NHANH

Đánh giá điện thoại Xiaomi Mi 8: có hối hận sau hơn 3 tháng sử dụng?

Điện thoại Xiaomi Mi 8 chính hãng là chiếc flagship được người dùng cũng như giới chuyên môn đánh giá khá cao, là đối thủ trực tiếp của iPhone X nhưng mức giá chỉ hơn 9 triệu đồng tại TCNShop. Hôm nay tôi sẽ đánh giá

Đánh giá chi tiết Galaxy J6: Có đáng lựa chọn trong tầm giá 5 triệu không?

Nhỏ và Dài là 2 cảm nhận đầu tiên của mình khi cầm vào Galaxy J6, dù là một thiết bị có màn hình đến 5,7 inch, nhưng cảm giác cầm chiếc J6 trên tay chỉ bằng cầm một chiếc iPhone “phiên bản không plus” với màn hình 4.7

Trên tay OPPO K9s – Smartphone hơn 5 triệu pin khủng, màn hình 120Hz siêu mượt

OPPO K9s nổi bật với giá bán hấp dẫn, màn hình siêu mượt 120Hz, pin trâu 5.000 mAh,… Đặc biệt, khi cầm trên tay OPPO K9s không hề có cảm giác rẻ tiền nhờ thiết kế có độ hoàn thiện cao, sang trọng và đẳng cấp. Trên tay